Diosgenin and GSK126 Produce Synergistic Effects on Epithelial–Mesenchymal Transition in Gastric Cancer Cells by Mediating EZH2 via the Rho/ROCK Signaling Pathway

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.2144229313949
   PubMed Web of Science ®Google Scholar
• Chen D, You X, Pan Y, Liu Q, Cao G. TRIM37 promotes cell invasion and metastasis by regulating SIP1-mediated epithelial-mesenchymal transition in gastric cancer. Onco Targets Ther. 2018;11:8803–8813. doi:10.2147/OTT.S17844630573971
   PubMed Web of Science ®Google Scholar
• Xu W, Yang Z, Lu N. Molecular targeted therapy for the treatment of gastric cancer. J Exp Clin Cancer Res. 2016;35:1. doi:10.1186/s13046-015-0276-926728266
   PubMed Web of Science ®Google Scholar
• Jiang M, Shi L, Yang C, et al. miR-1254 inhibits cell proliferation, migration, and invasion by down-regulating Smurf1 in gastric cancer. Cell Death Dis. 2019;10(1):32. doi:10.1038/s41419-018-1262-x30631050
   PubMedGoogle Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–196. doi:10.1038/nrm375824556840
   PubMed Web of Science ®Google Scholar
• Tanabe S, Aoyagi K, Yokozaki H, Sasaki H. Gene expression signatures for identifying diffuse-type gastric cancer associated with epithelial-mesenchymal transition. Int J Oncol. 2014;44(6):1955–1970. doi:10.3892/ijo.2014.238724728500
   PubMed Web of Science ®Google Scholar
• Peng F, Wu D, Gao B, et al. RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes. 2008;57(6):1683–1692. doi:10.2337/db07-114918356410
   PubMed Web of Science ®Google Scholar
• Kolavennu V, Zeng L, Peng H, Wang Y, Danesh FR. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes. 2008;57(3):714–723. doi:10.2337/db07-124118083785
   PubMed Web of Science ®Google Scholar
• Bhowmick NA, Ghiassi M, Bakin A, et al. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell. 2001;12(1):27–36. doi:10.1091/mbc.12.1.2711160820
   PubMed Web of Science ®Google Scholar
• Song GL, Jin CC, Zhao W, et al. Regulation of the RhoA/ROCK/AKT/β-catenin pathway by arginine-specific ADP-ribosytransferases 1 promotes migration and epithelial-mesenchymal transition in colon carcinoma. Int J Oncol. 2016;49(2):646. doi:10.3892/ijo.2016.353927277835
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu X, Liu Y, Yi B, Yu X. Epithelial–mesenchymal transition of rat peritoneal mesothelial cells via Rhoa/Rock pathway. In Vitro Cell Dev Biol Anim. 2011;47(2):165–172. doi:10.1007/s11626-010-9369-021108050
   PubMed Web of Science ®Google Scholar
• Yamada T, Hoshino M, Hayakawa T, et al. Dietary diosgenin attenuates subacute intestinal inflammation associated with indomethacin in rats. Am J Physiol. 1997;273(2 Pt 1):G355–G364. doi:10.1152/ajpgi.1997.273.2.G3559277414
   PubMedGoogle Scholar
• Son IS, Kim JH, Sohn HY, Son KH, Kim JS, Kwon CS. Antioxidative and hypolipidemic effects of diosgenin, a steroidal saponin of yam (Dioscorea spp.), on high-cholesterol fed rats. Biosci Biotechnol Biochem. 2007;71(12):3063–3071. doi:10.1271/bbb.7047218071250
   PubMed Web of Science ®Google Scholar
• Hou R, Zhou QL, Wang BX, Tashiro S, Onodera S, Ikejima T. Diosgenin induces apoptosis in HeLa cells via activation of caspase pathway. Acta Pharmacol Sin. 2004;25(8):1077–1082.15301743
   PubMed Web of Science ®Google Scholar
• Ying W, Chi-Ming C, Jen-Fu C, Qing-Yu H. Dioscin (saponin)-induced generation of reactive oxygen species through mitochondria dysfunction: a proteomic-based study. J Proteome Res. 2007;6(12):4703–4710. doi:10.1021/pr070399r17975908
   PubMed Web of Science ®Google Scholar
• Lv L, Zheng L, Dong D, et al. Dioscin, a natural steroid saponin, induces apoptosis and DNA damage through reactive oxygen species: a potential new drug for treatment of glioblastoma multiforme. Food Chem Toxicol. 2013;59:657–669. doi:10.1016/j.fct.2013.07.01223871826
   PubMed Web of Science ®Google Scholar
• Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G. Genome regulation by polycomb and trithorax proteins. Cell. 2007;128(4):735–745. doi:10.1016/j.cell.2007.02.00917320510
   PubMed Web of Science ®Google Scholar
• Asangani I, Ateeq B, Qi C, et al. Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol Cell. 2013;49(1):80–93. doi:10.1016/j.molcel.2012.10.00823159737
   PubMed Web of Science ®Google Scholar
• Yutaka K. Targeting histone methyltransferase EZH2 as cancer treatment. J Biochem. 2014;156(5):249–257. doi:10.1093/jb/mvu05425179367
   PubMed Web of Science ®Google Scholar
• Knutson SK, Warholic NM, Wigle TJ, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A. 2013;110(19):7922–7927. doi:10.1073/pnas.130380011023620515
   PubMed Web of Science ®Google Scholar
• Mccabe MT, Ott HM, Gopinath G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012;492(7427):108–112. doi:10.1038/nature1160623051747
   PubMed Web of Science ®Google Scholar
• Khan M, Walters LL, Li Q, et al. Characterization and pharmacologic targeting of EZH2, a fetal retinal protein and epigenetic regulator, in human retinoblastoma. Lab Invest. 2015;95(11):1278–1290. doi:10.1038/labinvest.2015.10426280220
   PubMed Web of Science ®Google Scholar
• Zeng D, Liu M, Pan J. Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells. Oncotarget. 2017;8(2):3396–3411. doi:10.18632/oncotarget.1377327926488
   PubMedGoogle Scholar
• Koppens MA, Bounova G, Cornelissen-Steijger P, et al. Large variety in a panel of human colon cancer organoids in response to EZH2 inhibition. Oncotarget. 2016;7(43):69816–69828. doi:10.18632/oncotarget.1200227634879
   PubMedGoogle Scholar
• Katona BW, Yuanyuan L, Anqi M, Jian J, Xianxin H. EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells. Cancer Biol Ther. 2014;15(12):1677–1687. doi:10.4161/15384047.2014.97277625535899
   PubMed Web of Science ®Google Scholar
• Grinshtein N, Rioseco CC, Marcellus R, et al. Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells. Oncotarget. 2016;7(37):59360–59376. doi:10.18632/oncotarget.1066127449082
   PubMedGoogle Scholar
• Yang Y, Zhu F, Wang Q, Ding Y, Ying R, Zeng L. Inhibition of EZH2 and EGFR produces a synergistic effect on cell apoptosis by increasing autophagy in gastric cancer cells. Onco Targets Ther. 2018;11:8455–8463. doi:10.2147/OTT.S18649830555238
   PubMed Web of Science ®Google Scholar
• Shishodia S, Aggarwal BB. Diosgenin inhibits osteoclastogenesis, invasion, and proliferation through the downregulation of Akt, I kappa B kinase activation and NF-kappa B-regulated gene expression. Oncogene. 2006;25(10):1463. doi:10.1038/sj.onc.120919416331273
   PubMed Web of Science ®Google Scholar
• Das S, Dey KK, Dey G, et al. Antineoplastic and apoptotic potential of traditional medicines thymoquinone and diosgenin in squamous cell carcinoma. PLoS One. 2012;7(10):e46641. doi:10.1371/journal.pone.004664123077516
   PubMed Web of Science ®Google Scholar
• Lepage C, Léger DY, Bertrand J, Martin F, Beneytout JL, Liagre B. Diosgenin induces death receptor-5 through activation of p38 pathway and promotes TRAIL-induced apoptosis in colon cancer cells. Cancer Lett. 2011;301(2):193–202. doi:10.1016/j.canlet.2010.12.00321195543
   PubMed Web of Science ®Google Scholar
• He Z, Chen H, Li G, et al. Diosgenin inhibits the migration of human breast cancer MDA-MB-231 cells by suppressing Vav2 activity. Phytomedicine. 2014;21(6):871–876. doi:10.1016/j.phymed.2014.02.00224656238
   PubMed Web of Science ®Google Scholar
• Jiang S, Fan J, Wang Q, et al. Diosgenin induces ROS-dependent autophagy and cytotoxicity via mTOR signaling pathway in chronic myeloid leukemia cells. Phytomedicine. 2016;23(3):243–252. doi:10.1016/j.phymed.2016.01.01026969378
   PubMed Web of Science ®Google Scholar
• Mao ZJ, Tang QJ, Zhang CA, et al. Anti-proliferation and anti-invasion effects of diosgenin on gastric cancer BGC-823 cells with HIF-1alpha shRNAs. Int J Mol Sci. 2012;13(5):6521–6533. doi:10.3390/ijms1305652122754381
   PubMed Web of Science ®Google Scholar
• Chen YT, Zhu F, Lin WR, Ying RB, Yang YP, Zeng LH. The novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis via down-regulating VEGF-A. Cancer Chemother Pharmacol. 2016;77(4):757–765. doi:10.1007/s00280-016-2990-126898301
   PubMed Web of Science ®Google Scholar
• Bate-Eya LT, Gierman HJ, Ebus ME, et al. Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity. Eur J Cancer. 2017;75:63–72. doi:10.1016/j.ejca.2016.12.01928214660
   PubMed Web of Science ®Google Scholar
• Wang C, Huo X, Wang L, et al. Dioscin strengthens the efficiency of adriamycin in MCF-7 and MCF-7/ADR cells through autophagy induction: more than just down-regulation of MDR1. Sci Rep. 2016;6:28403. doi:10.1038/srep2840327329817
   PubMed Web of Science ®Google Scholar
• Yang L, Tang L, Dai F, et al. Raf-1/CK2 and RhoA/ROCK signaling promote TNF-alpha-mediated endothelial apoptosis via regulating vimentin cytoskeleton. Toxicology. 2017;389:74–84. doi:10.1016/j.tox.2017.07.01028743511
   PubMed Web of Science ®Google Scholar
• Wang W, Du H, Liu H, Hu F, Liu G. SMAD specific E3 ubiquitin protein ligase 1 promotes ovarian cancer cell migration and invasion via the activation of the RhoA/ROCK signaling pathway. Oncol Rep. 2019;41(1):668–676. doi:10.3892/or.2018.683630542716
   PubMed Web of Science ®Google Scholar
• An H, Lin J, Sun H, et al. Biejiajian pills inhibits hepatoma carcinoma cell vasculogenic mimicry by suppressing RhoA/ROCK signaling pathway. Nan Fang Yi Ke Da Xue Xue Bao. 2018;38(8):997–1001. doi:10.3969/j.issn.1673-4254.2018.08.1630187871
   PubMedGoogle Scholar
• Chen X, Zhang S, Wang Z, et al. Supervillin promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma in hypoxia via activation of the RhoA/ROCK-ERK/p38 pathway. J Exp Clin Cancer Res. 2018;37(1):128. doi:10.1186/s13046-018-0787-229954442
   PubMedGoogle Scholar
• Li D, Wang H, Ding Y, et al. Targeting the NRF-2/RHOA/ROCK signaling pathway with a novel aziridonin, YD0514, to suppress breast cancer progression and lung metastasis. Cancer Lett. 2018;424:97–108. doi:10.1016/j.canlet.2018.03.02929580806
   PubMed Web of Science ®Google Scholar